###begin article-title 0
FGF9 can induce endochondral ossification in cranial mesenchyme
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
The flat bones of the skull (i.e., the frontal and parietal bones) normally form through intramembranous ossification. At these sites cranial mesenchymal cells directly differentiate into osteoblasts without the formation of a cartilage intermediate. This type of ossification is distinct from endochondral ossification, a process that involves initial formation of cartilage and later replacement by bone.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 402 406 402 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sox9</italic>
###xml 408 411 408 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ihh</italic>
###xml 413 419 413 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2a1</italic>
###xml 421 429 421 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10a1 </italic>
###xml 451 457 451 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CbfaI </italic>
###xml 461 472 461 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Osteocalcin</italic>
###xml 27 42 <span type="species:ncbi:10090">transgenic mice</span>
###xml 177 181 <span type="species:ncbi:10090">mice</span>
We have analyzed a line of transgenic mice that expresses FGF9, a member of the fibroblast growth factor family (FGF), in cranial mesenchymal cells. The parietal bones in these mice show a switch from intramembranous to endochondral ossification. Cranial cartilage precursors are induced to proliferate, then hypertrophy and are later replaced by bone. These changes are accompanied by upregulation of Sox9, Ihh, Col2a1, Col10a1 and downregulation of CbfaI and Osteocalcin. Fate mapping studies show that the cranial mesenchymal cells in the parietal region that show a switch in cell fate are likely to be derived from the mesoderm.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
These results demonstrate that FGF9 expression is sufficient to convert the differentiation program of (at least a subset of) mesoderm-derived cranial mesenchyme cells from intramembranous to endochondral ossification.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 522 523 522 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 781 782 781 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1305 1306 1305 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
Bone development can occur in two distinct ways: 1) through endochondral ossification where the mesenchymal cells differentiate into chondrocytes and lay down a cartilaginous template that is later replaced by bone; or 2) through intramembranous ossification where mesenchymal cells directly differentiate into osteoblasts without the formation of a cartilage intermediate. During endochondral ossification, the transcription factors Sox9, Sox5 and/or Sox6 are expressed and are involved in the induction of chondrocytes [1]. Chondrocytes in the growth plate are subsequently induced to exit the cell cycle and commit to terminal differentiation. The prehypertrophic chondrocytes mature into hypertrophic chondrocytes, which lay down a matrix rich in Collagen X, and secrete VEGF [2]. VEGF promotes the invasion of blood vessels from the perichondrium, bringing in both the bone forming osteoblasts and the bone resorbing osteoclasts. The hypertrophic chondrocytes then undergo apoptosis, and are replaced by trabecular bone and bone marrow. In contrast, the flat bones of the skull, the frontal and parietal bones, form by intramembranous ossification. Cranial mesenchymal cells directly differentiate into osteoblasts that initiate mineralization and secrete an extracellular matrix rich in Collagen I [3]. Growth of these calvarial bones occurs through proliferation and differentiation of osteoblasts at the margins or sutures. The molecular pathways that dictate these alternative ossification programs are not yet well defined. In particular, it is not known whether intramembranous ossification is prespecified by the ontogeny of the cranial mesenchyme or is a response to local environmental signals.
###end p 9
###begin p 10
###xml 88 89 88 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 244 245 244 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 536 537 536 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 538 539 538 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 771 772 771 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 945 946 945 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1060 1061 1060 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1137 1138 1137 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1447 1448 1447 1448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1449 1451 1449 1451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1704 1705 1704 1705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1706 1708 1706 1708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1821 1822 1821 1822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1971 1973 1971 1973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 2171 2173 2171 2173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 789 793 <span type="species:ncbi:10090">mice</span>
###xml 988 994 <span type="species:ncbi:9606">humans</span>
###xml 2014 2018 <span type="species:ncbi:10090">mice</span>
Fibroblast growth factors (FGFs) appear to be important for both types of ossification [4]. FGFs comprise a large family of proteins that includes at least 22 known members [5]. FGFs bind and signal through low and high affinity FGF receptors [5]. The four known high affinity receptors (FGFR1-4) are structurally similar transmembrane receptor tyrosine kinases. During intramembranous ossification of the flat bones, FGFR1-3 are expressed by the differentiating osteoblasts at the osteogenic fronts and also by the adjacent cartilage [6,7]. FGFR1 is expressed in cells close to and within the osteoid; FGFR2 is expressed in the proliferating osteogenic stem cells; FGFR3 expression is seen in the thin layer of cartilage underlying the lower part of the coronal suture [6]. As FGFR3 null mice do not show defects in calvarial development, it has been hypothesized that intramembranous bone formation is controlled primarily by FGFR1 and FGFR2 [8]. Mutations in FGFR1, FGFR2 and FGFR3 in humans that affect skeletal growth are consistent with this hypothesis [9]. Craniosynostosis is mainly associated with mutations in FGFR1 and FGFR2 [9]. Mutations that affect the growth of long bones resulting in syndromes such as Achondroplasia (Ach) and Thanatophoric dysplasia (TD) are mainly localized to FGFR3. These autosomal dominant disorders are believed to reflect either an enhancement of receptor activity or a neomorphic gain-of-function effect [9-11]. During long bone development, FGF receptors are expressed in the epiphyseal growth plates: FGFR3 is expressed in the proliferating chondrocytes; FGFR1 is expressed in the hypertrophic chondrocytes; FGFR1 and FGFR2 are expressed in the perichondrium [4,12]. FGFR2 is expressed in early mesenchymal condensates and in the periosteal collar around the cartilage models [8]. Targeted deletion of FGFR2IIIc suggests that FGFR2IIIc is a positive regulator of ossification in both the osteoblasts and chondrocytic lineages [13]. Targeted deletion of FGFR3 results in mice that show overgrowth of the long bones and abnormal proliferation of chondrocytes suggesting that FGFR3 stimulation inhibits chondrocyte proliferation [14]. These studies describe roles for FGF receptor-mediated signaling during differentiation/maturation of chondrocytes.
###end p 10
###begin p 11
###xml 92 97 92 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf8 </italic>
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf2 </italic>
###xml 139 144 139 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf4 </italic>
###xml 185 191 185 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf18 </italic>
###xml 294 295 294 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 298 303 298 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf9 </italic>
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 755 757 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 849 854 849 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf9 </italic>
###xml 897 899 897 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 902 906 902 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf2</italic>
###xml 908 912 908 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf5</italic>
###xml 914 919 914 919 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf6 </italic>
###xml 923 928 923 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf7 </italic>
###xml 988 990 988 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 991 993 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1079 1081 1079 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1082 1084 1082 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1005 1009 <span type="species:ncbi:10090">mice</span>
The roles of FGF ligands in skeletal development are unclear. During calvarial development, Fgf8 is expressed in the osteoblasts; Fgf2 and Fgf4 are expressed in the sutural mesenchyme; Fgf18 is initially expressed in the cranial mesenchymal cells and later, in the differentiating osteoblasts [8]. Fgf9 is expressed in the sutural mesenchyme and is upregulated in the endocranial portions of the mesenchyme and is downregulated during postnatal development [15][16]. The specific in vivo functions of these different FGFs remain undefined. In vitro, cephalic neural crest cells from quail embryos have been shown to respond to exogenous FGF-2 in a dose dependant manner; lower doses induce proliferation and higher doses induce cartilage differentiation [17]. During long bone development, at the time of initiation of endochondral differentiation, Fgf9 is expressed in the condensing mesenchyme [18]. Fgf2, Fgf5, Fgf6 and Fgf7 are expressed in loose mesenchyme outside the condensation [19-23]. However, mice lacking these Fgfs show no apparent defects in skeletal development [24-28]. Functional redundancy between these FGFs may, in part, account for the lack of phenotype. Therefore, roles for these Fgfs in the early stages of chondrogenesis have not yet been defined.
###end p 11
###begin p 12
###xml 535 539 535 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sox9</italic>
###xml 541 547 541 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2a1</italic>
###xml 549 556 549 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10a1</italic>
###xml 558 561 558 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ihh</italic>
###xml 563 569 563 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CbfaI </italic>
###xml 573 585 573 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Osteocalcin </italic>
###xml 32 47 <span type="species:ncbi:10090">transgenic mice</span>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
###xml 229 233 <span type="species:ncbi:10090">mice</span>
###xml 681 685 <span type="species:ncbi:10090">mice</span>
###xml 862 866 <span type="species:ncbi:10090">mice</span>
In this study, we have analyzed transgenic mice that express FGF9 in their cranial mesenchymal cells. These mice show abnormal head development and are born with a pronounced bulge in their skulls. Skeletal preparations of these mice revealed dramatic changes in parietal bone formation. In the region where the parietal bones normally form, cranial mesenchymal cells are induced to differentiate into chondrocytes that proliferate, hypertrophy and subsequently differentiate as bone. Correlative changes in expression of marker genes Sox9, Col2a1, Col10a1, Ihh, CbfaI and Osteocalcin occur in conjunction with the altered differentiation program. Thus the parietal bones in these mice form by endochondral ossification rather than by the usual intramembranous ossification route. Fate mapping studies indicate that the ectopic cartilagenous precursors in these mice are derived from the mesoderm. Based on these results we suggest that cranial mesenchymal cells are competent to initiate endochondral ossification, and can be switched to this alternative developmental program by ectopic expression, or overexpression, of FGF9.
###end p 12
###begin title 13
Results
###end title 13
###begin title 14
###xml 42 57 <span type="species:ncbi:10090">transgenic mice</span>
Changes in cranial morphology in the FGF9 transgenic mice
###end title 14
###begin p 15
###xml 118 123 114 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf9 </italic>
###xml 134 136 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 139 141 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 363 368 359 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B, C</xref>
###xml 471 473 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 112 117 <span type="species:ncbi:10090">mouse</span>
###xml 371 375 <span type="species:ncbi:10090">Mice</span>
###xml 529 544 <span type="species:ncbi:10090">transgenic mice</span>
Transgenic mice were generated by microinjection of a construct with the alphaA-crystallin promoter linked to a mouse Fgf9 cDNA (Fig. 1A) [29]. Eleven founders carrying the transgene were identified. Five of them had cataracts (data not shown). In the transgenic line OVE1070, in addition to lens defects, there were defects in the development of the skull (Fig. 1B, C). Mice in this family that are heterozygous for the transgene are born with 'dome-shaped' heads (Fig. 1C). This phenotype is even more pronounced in homozygous transgenic mice (data not shown).
###end p 15
###begin p 16
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf9 </italic>
###xml 344 347 336 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sst</italic>
###xml 46 61 <span type="species:ncbi:10090">transgenic mice</span>
###xml 148 153 <span type="species:ncbi:10090">mouse</span>
###xml 282 286 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 365 369 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 508 523 <span type="species:ncbi:10090">transgenic mice</span>
###xml 552 567 <span type="species:ncbi:10090">transgenic mice</span>
###xml 603 618 <span type="species:ncbi:10090">transgenic mice</span>
###xml 700 715 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1052 1067 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1227 1242 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1478 1493 <span type="species:ncbi:10090">transgenic mice</span>
Abnormal head development in the OVE1070 FGF9 transgenic mice. Panel A shows a schematic representation of the FGF9 transgene. The coding region of mouse Fgf9 cDNA was inserted between the alphaA-crystallin promoter (alphaAp) and an intron and polyadenylation sequence derived from SV40 virus [47]. The microinjection fragment was generated by SstII digestion. The SV40 sequences were used to make a riboprobe for detection of expression of the transgene. (B and C) Three day old nontransgenic (NT) and FGF9 transgenic mice are shown. The heads of the transgenic mice are 'dome' shaped (C). The OVE1070 transgenic mice often show unfused eyelids at birth (C). (D-K) Skeletal preparations of the FGF9 transgenic mice reveal an expansion in the cartilage territory in the head region. Alcian blue and Alizarin red stained E15 (D and E), P3 (F and G), P10 (H and I) and P30 (J and K) heads are shown. Cartilage is stained blue and bone red. The insets in panels D and E are higher magnifications of the frontal and parietal bones in the nontransgenic and transgenic mice respectively. The insets in panels F-I are rear views. The insets in panels J and K are top views. An expansion in the cartilage territory is seen in the FGF9 transgenic mice. Parietal bone (p) is affected in the transgenic skulls but the coronal suture is still present (E inset, arrow). Frontal (f) and occipital bone formation appear to be unaffected (E and G insets). A hole forms in the skull of the FGF9 transgenic mice that is visible by P3 (G inset, arrow) and is seen to persist at P10 (I inset, arrow). The red stain visible at the arrow in the inset in panel G is bone at the base of the head, which is visible since the skull and the brain are transparent after staining and clearing. The cartilage territory is replaced by bone by P30 (K and inset). Scale bar: 1 mm in D and E; 1.6 mm in F and G; 2.5 mm in H-K.
###end p 16
###begin title 17
###xml 30 45 <span type="species:ncbi:10090">transgenic mice</span>
Calvarial development in FGF9 transgenic mice
###end title 17
###begin p 18
###xml 111 115 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D&#8211;K</xref>
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1E</xref>
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D</xref>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1E</xref>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1F</xref>
###xml 617 619 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1G</xref>
###xml 728 730 728 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1G</xref>
###xml 804 806 804 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1G</xref>
###xml 1021 1023 1021 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1I</xref>
###xml 1107 1109 1107 1109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1K</xref>
###xml 100 104 <span type="species:ncbi:10090">mice</span>
###xml 376 391 <span type="species:ncbi:10090">transgenic mice</span>
###xml 465 469 <span type="species:ncbi:10090">mice</span>
###xml 595 610 <span type="species:ncbi:10090">transgenic mice</span>
###xml 626 641 <span type="species:ncbi:10090">transgenic mice</span>
The skeletal defects were examined by Alcian blue and Alizarin red staining of E15, P3, P10 and P30 mice (Fig. 1D-K). The skeletal preparations show a dramatic expansion of cartilage in the head region by E15 (compare Fig. 1E to 1D). Parietal bone development was particularly affected (Fig. 1E and inset). At P3, the phenotypic differences between the nontransgenic and FGF9 transgenic mice were still pronounced. At this age, the calvarial skull in nontransgenic mice is mostly ossified except at the sutures (Fig. 1F). In contrast, there is an expanded cartilage territory (blue) in the FGF9 transgenic mice (Fig. 1G). The transgenic mice also show a central hole in the skull where there is neither cartilage nor bone (Fig. 1G, inset, arrow). Development of the occipital bones appeared normal (Fig. 1G and inset). At P10, the Alcian blue stained tissues in the transgenic cranium were interspersed with Alizarin red stained regions suggesting that the cartilage territory was being replaced by bony structures (Fig. 1I). By 1 month of age, the cartilage territory was completely replaced by bone (Fig. 1K and inset).
###end p 18
###begin p 19
###xml 357 363 357 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B, B'</xref>
###xml 446 451 446 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A, B</xref>
###xml 567 573 567 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C, C'</xref>
###xml 704 710 704 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2D, D'</xref>
###xml 798 811 798 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2F, F', H, H'</xref>
###xml 921 927 921 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2J, J'</xref>
###xml 1021 1027 1021 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2L, L'</xref>
###xml 52 67 <span type="species:ncbi:10090">transgenic mice</span>
###xml 335 350 <span type="species:ncbi:10090">transgenic mice</span>
###xml 427 431 <span type="species:ncbi:10090">mice</span>
###xml 513 517 <span type="species:ncbi:10090">mice</span>
###xml 1139 1143 <span type="species:ncbi:10090">mice</span>
The alterations in skeletal development in the FGF9 transgenic mice were examined at the histological level by analyses of hematoxylin and eosin stained sections of the cranium. No distinctive differences in morphology were seen at E11 (data not shown). By E13, more cranial mesenchymal cells were seen in the skull region of the FGF9 transgenic mice (Fig. 2B, B') and these cells were organized differently from nontransgenic mice (compare Fig. 2A, B). By E15, the cranial mesenchymal cells in the nontransgenic mice had initiated intramembranous ossification (Fig. 2C, C', arrow). In contrast, the mesenchymal cells in the FGF9 transgenic skulls differentiated into cells resembling chondrocytes (Fig. 2D, D'). Within the next few days these cells increased in size and became hypertrophic (Fig. 2F, F', H, H'). By P7, perichondrial cells (including the blood vessels) had begun to invade the cartilage territory (Fig. 2J, J'). By P18, the cartilage territory was transformed into trabecular bone and bone marrow (Fig. 2L, L'). These results considered together suggest that the cranial mesenchymal cells in the parietal region in these mice recapitulate the sequence of events that occurs during endochondral ossification.
###end p 19
###begin p 20
###xml 31 46 <span type="species:ncbi:10090">transgenic mice</span>
###xml 159 174 <span type="species:ncbi:10090">transgenic mice</span>
###xml 381 385 <span type="species:ncbi:10090">mice</span>
###xml 522 537 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1058 1062 <span type="species:ncbi:10090">mice</span>
Cranial mesenchyme in the FGF9 transgenic mice differentiates into chondrocytes. Heads of nontransgenic (A, A', C, C', E, E', G, G', I, I', K and K') and FGF9 transgenic mice (B, B', D, D', F, F', H, H', J, J', L and L') were sectioned and stained with hematoxylin and eosin. Panels A'-L' are higher magnifications of the boxed regions in panels A-L respectively. In nontransgenic mice, the mesenchymal cells of the skull form a skeletogenic membrane (arrows in A', C', E' and G') within which the bones form. In the FGF9 transgenic mice the cranial mesenchymal cells (cm) differentiate into chondrocytes (ch) that initially form a structure resembling the hyaline cartilage (D, D', F and F') and later hypertrophy (hyp) (H, H', J and J'). Perichondrial cells, including blood cells (J', arrows) invade and replace the hypertophic chondrocytes forming bone and bone marrow (L and L'). Other abbreviations: b, brain; s, skin. The folding seen in the section in panel G is an artifact of the histology procedure. Note that the skin was removed from P7 and P18 mice to facilitate fixation and histological processing. Scale bar: 50 mum in A'-L'; 100 mum in A, B, C, D, E, H, I and K; 200 mum in F, G, J and L.
###end p 20
###begin title 21
Ectopic expression of the FGF9 transgene
###end title 21
###begin p 22
###xml 163 165 163 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 419 430 419 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B', D', F'</xref>
###xml 498 505 498 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3D', F'</xref>
###xml 757 759 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3G</xref>
###xml 61 65 <span type="species:ncbi:10090">mice</span>
###xml 205 209 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
To test if the alterations seen in the skulls of the OVE1070 mice were due to ectopic expression of the transgene, in situ hybridizations were performed using an S35-labelled riboprobe that recognizes the SV40 portion of the transgene (Fig. 1A). Transgene expression was seen in the lens [29], the dorsal portion of the retinal pigmented epithelium [30] and also in the cranial mesenchymal cells beginning at E11 (Fig. 3B', D', F'). Expression levels peak by E13 and start to decrease by E15 (Fig. 3D', F'). Transgene expression is extinguished by E17 (data not shown). Section and whole mount in situ hybridizations show that the extraocular transgene expression is restricted to the mesenchymal cells overlying the future mid and hind brain regions (Fig. 3G, arrows; 3H-M). These results argue that the defects in skeletal development in the OVE1070 line are attributable to ectopic and transient expression of the FGF9 transgene.
###end p 22
###begin p 23
###xml 149 151 149 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 124 139 <span type="species:ncbi:10090">transgenic mice</span>
###xml 162 166 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 725 729 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
Expression pattern of the transgene. In situ hybridizations were done on sections of heads from nontransgenic (NT) and FGF9 transgenic mice using a [35S]-labeled SV40 riboprobe. Panels A-F show bright-field images and panels A'-F' show the corresponding dark field images. Transgene expression can be seen in the cranial mesenchymal cells at E11 (B'), E13 (D') and E15 (F'). At later stages, expression of the transgene in the cranium was not detected (data not shown). Transgene expression was restricted to the mesenchymal cells overlying the mid (m) to hind brain regions (h) but not the forebrain (f) (G, arrows). Scale bar: 100 mum in A-F'. Whole mount in situ hybridizations on E12.5 heads using a digoxygenin-labelled SV40 riboprobe show expression of the transgene (purple color) in the cranial regions (H-K). Panels H and I are rear views and panels J and K are top views. Scale bar: 1 mm in H, I and K.
###end p 23
###begin title 24
Expression of chondrocyte specific markers
###end title 24
###begin p 25
###xml 123 127 123 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sox9</italic>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 263 268 263 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sox9 </italic>
###xml 374 380 374 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2a1</italic>
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 420 427 420 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2a1 </italic>
###xml 487 491 487 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ihh </italic>
###xml 526 534 526 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10a1 </italic>
###xml 563 564 563 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 618 624 618 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CbfaI </italic>
###xml 717 719 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 768 773 768 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CbfaI</italic>
###xml 820 822 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 907 909 907 909 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 937 938 937 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 943 944 943 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 991 996 991 996 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sox9 </italic>
###xml 1066 1079 1066 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A, A', B, B'</xref>
###xml 1116 1121 1116 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sox9 </italic>
###xml 1210 1219 1210 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C, C', D</xref>
###xml 1224 1227 1224 1227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4D'</xref>
###xml 1230 1235 1230 1235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sox9 </italic>
###xml 1303 1309 1303 1309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4F, F'</xref>
###xml 1312 1318 1312 1318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CbfaI </italic>
###xml 1322 1334 1322 1334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Osteocalcin </italic>
###xml 1532 1537 1532 1537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4G&#8211;J'</xref>
###xml 1027 1042 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1181 1196 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1423 1427 <span type="species:ncbi:10090">mice</span>
The different stages of endochondral ossification are characterized by expression of different marker genes. Expression of Sox9, a member of the Sox family of transcription factors, has been shown to be essential for chondrocyte condensation [31]. In particular, Sox9 is required for the expression of cartilage-specific extracellular matrix components such as Collagen II (Col2a1) [32]. In the long bone growth plates, Col2a1 is expressed in the resting and proliferating chondrocytes, Ihh in prehypertropic chondrocytes and Col10a1 in hypertropic chondrocytes [3]. Expression of the runt domain transcription factor CbfaI has been shown to be essential for differentiation of the cells in the osteoblastic lineage [33]. Osteocalcin, one of the downstream targets of CbfaI, is expressed exclusively in the osteoblasts [34]. Expression of these six marker genes was examined by in situ hybridization using S35-labelled riboprobes (Figs. 4 and 5). No appreciable differences in expression of Sox9 between nontransgenic and FGF9 transgenic mice were seen at E11 (Fig. 4A, A', B, B'). However, significant induction of Sox9 expression was seen in the cranial mesenchymal cells of the transgenic mice by E13 (Fig. 4C, C', D and 4D'). Sox9 expression was seen to persist in the developing chondrocytes (Fig. 4F, F'). CbfaI and Osteocalcin are expressed during the normal program of intramembranous ossification in nontransgenic mice, but their expression was not seen in the corresponding regions of the embryonic transgenic heads (Fig. 4G-J').
###end p 25
###begin p 26
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sox9</italic>
###xml 29 35 29 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CbfaI </italic>
###xml 39 50 39 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Osteocalcin</italic>
###xml 162 164 162 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 190 195 190 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sox9 </italic>
###xml 203 209 203 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CbfaI </italic>
###xml 220 232 220 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">osteocalcin </italic>
###xml 347 352 347 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sox9 </italic>
###xml 437 442 437 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sox9 </italic>
###xml 568 574 568 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CbfaI </italic>
###xml 578 590 578 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">osteocalcin </italic>
###xml 139 154 <span type="species:ncbi:10090">transgenic mice</span>
###xml 408 423 <span type="species:ncbi:10090">transgenic mice</span>
###xml 553 557 <span type="species:ncbi:10090">mice</span>
###xml 671 675 <span type="species:ncbi:10090">mice</span>
###xml 726 741 <span type="species:ncbi:10090">transgenic mice</span>
Expression patterns of Sox9, CbfaI and Osteocalcin. In situ hybridizations were done on sections of heads from nontransgenic (NT) and FGF9 transgenic mice using [35S]-labeled riboprobes for Sox9 (A-F'), CbfaI (G-H') and osteocalcin (I-J'). Panels A-J are bright field images and panels A'-J' are the corresponding dark-field images. Expression of Sox9 is induced in the cranial mesenchymal cells of the FGF9 transgenic mice by E13 (D'). Sox9 expression is detected in the ventricular regions of the brain at E13 in both the transgenic and nontransgenic mice (C', D'). CbfaI and osteocalcin are expressed in the differentiating calvarial osteoblasts (os) of nontransgenic mice at E15 (G', I') but not in the skulls of the FGF9 transgenic mice (H', J'). Scale bar: 50 mum in G-J'; 100 mum in A-F'.
###end p 26
###begin p 27
###xml 23 29 23 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2a1</italic>
###xml 31 39 31 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10a1 </italic>
###xml 43 46 43 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ihh</italic>
###xml 158 160 158 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 186 192 186 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2a </italic>
###xml 200 208 200 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10a1 </italic>
###xml 219 223 219 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ihh </italic>
###xml 338 345 338 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2a1 </italic>
###xml 538 546 538 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10a1 </italic>
###xml 135 150 <span type="species:ncbi:10090">transgenic mice</span>
###xml 402 417 <span type="species:ncbi:10090">transgenic mice</span>
Expression patterns of Col2a1, Col10a1 and Ihh. In situ hybridizations were done on sections of heads from nontransgenic (NT) and FGF9 transgenic mice using [35S]-labeled riboprobes for Col2a (A-H'), Col10a1 (I-J') and Ihh (K-L'). Panels A-L are bright field images and panels A'-L' are the corresponding dark-field images. Expression of Col2a1 is enhanced in the cranial mesenchymal cells of the FGF9 transgenic mice by E15 (B') and is decreased in some cells by P7 (H'). Hybridizations performed on adjacent sections show expression of Col10a1 in these hypertropic (hyp) chondrocytes (J'). Ihh expression was detected in the differentiated chondrocytes by P7 (L'). Abbreviations: b, brain; ch, chondrocytes; hyp, hypertropic chondrocytes; os, osteoblasts; s, skin. Scale bar: 100 mum in A-L'.
###end p 27
###begin p 28
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2a1 </italic>
###xml 131 136 131 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A&#8211;F'</xref>
###xml 233 238 233 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5E&#8211;H'</xref>
###xml 282 290 282 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10a1 </italic>
###xml 294 298 294 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ihh </italic>
###xml 350 355 350 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5I&#8211;L'</xref>
###xml 372 380 372 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10a1 </italic>
Col2a1 expression was seen in the developing chondrocytes in the transgenic cranium but not the wildtype, at E15, E17 and P3 (Fig. 5A-F'). By P3 expression levels were found to be reduced in transgenic hypertropic chondrocytes (Fig. 5E-H'). In situ hybridizations at P7 showed that Col10a1 and Ihh are expressed in the hypertropic chondrocytes (Fig. 5I-L'). Expression of Col10a1 was not seen in the chondrocytes at P3 or before (data not shown). These results demonstrate that the transgenic cranial mesenchymal cells undergo endochondral ossification instead of intramembranous ossification.
###end p 28
###begin title 29
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf9</italic>
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2 </italic>
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr3</italic>
Expression of Fgf9, Fgfr2 and Fgfr3
###end title 29
###begin p 30
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf9 </italic>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 161 166 161 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf9 </italic>
###xml 191 196 191 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf9 </italic>
###xml 246 248 246 248 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 260 265 260 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf9 </italic>
###xml 281 286 281 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A&#8211;D'</xref>
###xml 305 310 305 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf9 </italic>
###xml 418 423 418 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf9 </italic>
###xml 483 488 483 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A&#8211;D'</xref>
###xml 399 403 <span type="species:ncbi:10090">mice</span>
###xml 461 476 <span type="species:ncbi:10090">transgenic mice</span>
Fgf9 has been reported to be expressed in cranial mesenchymal cells as well as in the dural mesoderm during embryonic development [16]. Expression levels of the Fgf9 transgene and endogenous Fgf9 were compared by in situ hybridizations using an [35S]-labelled Fgf9 riboprobe (Fig. 6A-D'). At E11 and E13, Fgf9 was not expressed at detectable levels in the cranial mesenchymal cells in nontransgenic mice. In contrast, Fgf9 expression was clearly present in the transgenic mice (Fig. 6A-D').
###end p 30
###begin p 31
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf9</italic>
###xml 29 35 29 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2 </italic>
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr3</italic>
###xml 156 158 156 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 184 189 184 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf9 </italic>
###xml 197 203 197 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2 </italic>
###xml 214 220 214 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr3 </italic>
###xml 335 340 335 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf9 </italic>
###xml 521 527 521 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2 </italic>
###xml 709 715 709 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr3 </italic>
###xml 133 148 <span type="species:ncbi:10090">transgenic mice</span>
###xml 411 415 <span type="species:ncbi:10090">mice</span>
###xml 631 635 <span type="species:ncbi:10090">mice</span>
Expression patterns of Fgf9, Fgfr2 and Fgfr3. In situ hybridizations were done on sections of heads from nontransgenic (NT) and FGF9 transgenic mice using [35S]-labeled riboprobes for Fgf9 (A-D'), Fgfr2 (E-H') and Fgfr3 (I-L'). Panels A-L are bright field images and panels A'-L' are the corresponding dark-field images. Expression of Fgf9 is not seen in the cranial mesenchymal (cm) cells of the nontransgenic mice at E11 (A') or E13 (C') in contrast to age-matched sections of FGF9 transgenic heads (B' and D'). Modest Fgfr2 expression is detected in the cranial mesenchymal cells at E11 in both the transgenic and nontransgenic mice (E' and F') and persists in the expanded cranial mesenchyme at E13 (H'). Fgfr3 expression is initially not seen in the cranial mesenchymal (cm) cells at E11 (J') but low level expression can be detected in the transgenic mesenchyme at E13 (L'). Scale bar: 100 mum in A-L'.
###end p 31
###begin p 32
###xml 133 138 133 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6E-L'</xref>
###xml 155 161 155 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2 </italic>
###xml 272 281 272 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6E, E', F</xref>
###xml 286 289 286 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6F'</xref>
###xml 292 298 292 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2 </italic>
###xml 380 386 380 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6H, H'</xref>
###xml 402 408 402 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr3 </italic>
###xml 509 522 509 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6I, I', J, J'</xref>
###xml 525 531 525 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr3 </italic>
###xml 629 635 629 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6L, L'</xref>
###xml 699 701 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 250 265 <span type="species:ncbi:10090">transgenic mice</span>
###xml 358 373 <span type="species:ncbi:10090">transgenic mice</span>
###xml 607 622 <span type="species:ncbi:10090">transgenic mice</span>
###xml 672 676 <span type="species:ncbi:10090">mice</span>
###xml 693 697 <span type="species:ncbi:10090">mice</span>
###xml 836 851 <span type="species:ncbi:10090">transgenic mice</span>
As FGF9 binds to and signals through FGFR2 and FGFR3, in situ hybridizations were performed to examine their expression levels (Fig. 6E-L'). Low levels of Fgfr2 expression can be seen in cranial mesenchymal cells at E11 in both the nontransgenic and transgenic mice (Fig. 6E, E', F and 6F'). Fgfr2 expression is maintained in the induced chondrocytes in the transgenic mice (Fig. 6H, H'). In contrast, Fgfr3 expression was not detected at E11 either in transgenic or in nontransgenic cranial mesenchyme (Fig. 6I, I', J, J'). Fgfr3 was expressed at low levels in the differentiating chondrocytes of the FGF9 transgenic mice (Fig. 6L, L'). In addition, crossing the OVE1070 mice with FGFR3 null mice [14] does not alter the "dome-head" phenotype (data not shown). These results taken together suggest that the developmental switch in the transgenic mice may initially be mediated by ectopic activation of FGFR2.
###end p 32
###begin title 33
FGF9 induces proliferation of the cranial mesenchymal cells
###end title 33
###begin p 34
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 313 317 313 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A&#8211;D</xref>
###xml 241 256 <span type="species:ncbi:10090">transgenic mice</span>
To test if the cranial mesenchymal cells proliferate in response to FGF9 expression, sections of E11 and E13 skulls were assayed for BrdU incorporation (Fig. 7). At E11 and at 13, the cranial mesenchymal cells in the parietal region of FGF9 transgenic mice show a significant increase in BrdU incorporation (Fig. 7A-D). These results suggest that FGF9 expression in the cranial mesenchymal cells results in increased proliferation.
###end p 34
###begin p 35
###xml 237 252 <span type="species:ncbi:10090">transgenic mice</span>
BrdU incorporation and cell proliferation. BrdU incorporation (brown stain) was detected by immunohistochemistry (A-D). A significant increase in BrdU positive (brown stained nuclei) cells was detected in the parietal region of the FGF9 transgenic mice at E11 and at E13 (E). Scale bar: 100 mum in A-D.
###end p 35
###begin title 36
###xml 57 72 <span type="species:ncbi:10090">transgenic mice</span>
Fate mapping of cells in the parietal region in the FGF9 transgenic mice
###end title 36
###begin p 37
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 380 382 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 576 578 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 579 581 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 689 690 686 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 721 726 718 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ </italic>
###xml 918 923 915 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ </italic>
###xml 42 46 <span type="species:ncbi:10090">mice</span>
###xml 263 267 <span type="species:ncbi:10090">mice</span>
###xml 374 378 <span type="species:ncbi:10090">mice</span>
###xml 592 596 <span type="species:ncbi:10090">mice</span>
###xml 629 633 <span type="species:ncbi:10090">mice</span>
###xml 1232 1236 <span type="species:ncbi:10090">mice</span>
Cell lineage tracing studies performed in mice and in chicks show that the cranial skeletogenic mesenchyme is derived from two sources, neural crest and mesoderm [35-37]. To determine if the cells in the parietal region that form ectopic cartilage in the OVE1070 mice are neural crest or mesodermal derivatives, we performed fate mapping experiments using Wnt1-Cre and R26R mice [38,39]. As has been described previously, Wnt1-Cre/R26R compound heterozygotes stably express beta-galactosidase in neural crest cells and their descendants but not in the mesodermal derivatives [40,41]. OVE1070 mice were crossed with Wnt1-Cre/R26R mice and heads of E17 embryos were stained with X-Gal (Fig. 8). In the absence of Wnt1-Cre, lacZ positive cells were not detected in the R26R embryo (A, A') or in the FGF9/R26R embryo (B, B'). In the Wnt1-Cre/R26R embryo (C,C'), the parietal region (p) of the skull showed no evidence for lacZ activity, implying that neural crest derivatives do not contribute to this region of the skull. In the FGF9/Wnt1-Cre/R26R embryo (D, D'), there is also no blue staining in the (enlarged) parietal region. These results establish that the cells in the parietal region that form ectopic cartilage in the OVE1070 mice are not neural crest derived but are for the most part, derived from mesoderm. In summary, in family OVE1070, ectopic FGF9 expression switches the differentiation and proliferation properties of cranial mesodermal cells, resulting in inhibition of intramembranous ossification and conversion to a program of endochondral ossification.
###end p 37
###begin p 38
###xml 181 186 181 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ </italic>
###xml 375 380 375 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ </italic>
###xml 855 870 <span type="species:ncbi:10090">transgenic mice</span>
Fate mapping studies in the OVE1070 cranium. X-Gal staining of E17 embryos. Panels A-D are top views and panels A'-D' are lateral views of intact heads. In the absence of Wnt1-Cre, lacZ positive cells were not detected in the R26R embryo (A, A') or the FGF9/R26R embryo (B, B'). In the Wnt1-Cre/R26R embryo (C, C'), the parietal region (p) of the skull shows no evidence for lacZ activity, implying that neural crest cells do not contribute to this region of the skull. In the FGF9/Wnt1-Cre/R26R embryo (D, D'), there is also no blue staining in the (enlarged) parietal region. In order to distinguish the staining in the skull (E) from the staining in the underlying brain (F, asterisk), the calvarium was removed intact from embryo D and the two parts of the head are shown as top views (E, F). Since the dorsal retinal pigmented epithelium in the FGF9 transgenic mice transdifferentiates into the neural retina [30], pigmentation is seen only in the ventral half of the eye (B', arrow). Abbreviations: f, frontal; ip, interparietal.
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 385 390 385 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sox9 </italic>
###xml 423 429 423 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CbfaI </italic>
###xml 433 444 433 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Osteocalcin</italic>
###xml 526 532 526 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2a1</italic>
###xml 592 599 592 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10a1</italic>
###xml 42 57 <span type="species:ncbi:10090">transgenic mice</span>
###xml 199 214 <span type="species:ncbi:10090">transgenic mice</span>
###xml 702 706 <span type="species:ncbi:10090">mice</span>
In this study, we have analyzed a line of transgenic mice where the differentiation program of a portion of the cranial mesenchyme is converted from intramembranous to endochondral ossification. The transgenic mice ectopically express FGF9 in their cranial mesenchymal cells. Expression of FGF9 correlates with localized proliferation of the mesenchymal cells and with upregulation of Sox9 expression and downregulation of CbfaI and Osteocalcin. The mesenchymal cells consequently differentiate into chondrocytes that express Col2a1. These chondrocytes proliferate, then hypertrophy, express Col10a1and are later replaced by trabecular bone and bone marrow. Therefore, parietal bone formation in these mice recapitulates the sequence of events that occurs during endochondral ossification. These results demonstrate that FGF9 expression is sufficient to convert the differentiation program of (at least a subset of) the cranial mesenchymal cells from intramembranous to endochondral ossification.
###end p 40
###begin title 41
Ectopic expression of the transgene
###end title 41
###begin p 42
###xml 703 705 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3G</xref>
###xml 751 756 751 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sox9 </italic>
###xml 1125 1127 1125 1127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1225 1230 1225 1230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sox9 </italic>
###xml 1231 1233 1231 1233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1363 1365 1363 1365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 64 68 <span type="species:ncbi:10090">mice</span>
###xml 202 206 <span type="species:ncbi:10090">mice</span>
###xml 394 398 <span type="species:ncbi:10090">mice</span>
###xml 911 916 <span type="species:ncbi:10090">mouse</span>
###xml 1489 1493 <span type="species:ncbi:10090">mice</span>
The skeletal defects in this transgenic line (OVE1070) occur in mice that are either heterozygous or homozygous for the FGF9 transgene. It is, therefore, unlikely that the skull defects in this line of mice are due to disruption of a gene essential for membranous ossification of the parietal bones. The transgene expression pattern provides compelling evidence that the skull defects in these mice are due to ectopic expression of the transgene. In situ hybridization analyses show that the transgene is expressed in an appropriate spatial and temporal pattern to induce the developmental changes. In addition, the transgene is not expressed in regions where membranous ossification still occurs (Fig. 3G). Furthermore, transgene expression precedes Sox9 expression and condensation of the mesenchymal cells. Also, our results are consistent with the results of other studies. For example, recent studies of a mouse model for Apert syndrome, with a single amino acid change in FGFR2, support the notion that enhanced activation of FGFR2 can cause some cranial mesenchyme to convert to a chondrocyte differentiation program [10]. In addition, FGF9 expression in a chondrocytic cell line is sufficient to induce expression of Sox9 [42]. Addition of FGF-2 in vitro to cranial mesenchymal cells from quail embryos can induce cartilage differentiation at high doses [17]. Taken together, these results suggest that initiation of chondrogenesis in the cranial mesenchymal cells in this line of mice is due to ectopic expression of the FGF9 transgene.
###end p 42
###begin p 43
In the OVE1070 family, expression of the FGF9 transgene is not only ectopic but also transient. Expression in the cranial mesenchyme was not detectable after E15. This implies that stimulation by FGF9 is sufficient to induce (competent) cranial mesoderm to switch to a chondrocytic differentiation program, but sustained expression of FGF9 is not required for the later stages of differentiation. Therefore, the endochondral ossification program, once initiated by FGF9, appears to become autonomous.
###end p 43
###begin p 44
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf9 </italic>
###xml 365 367 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 523 525 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
The reason for the ectopic Fgf9 expression is not clear at present. It is possible the transgene array has integrated in the neighborhood of an endogenous enhancer that directs expression to the cranial mesenchymal cells. Some of the integrated copies of the transgene still retain the alphaA-crystallin promoter since the transgene is still expressed in the lens [30]. The transgene is also expressed in the dorsal margins of the retinal pigmented epithelium (RPE) and this expression transforms the RPE into neuroretina [30].
###end p 44
###begin title 45
Nature of FGF9 induction
###end title 45
###begin p 46
###xml 58 65 58 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2a1 </italic>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 756 763 756 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2a1 </italic>
###xml 1400 1402 1400 1402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1403 1405 1403 1405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1547 1548 1547 1548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 259 263 <span type="species:ncbi:10090">mice</span>
Expression of FGF9 in growth plate chondrocytes using the Col2a1 promoter results in reduced proliferation and terminal differentiation of chondrocytes [43]. In addition, targeted deletion of FGFR3, one of the receptors through which FGF9 signals, results in mice with overgrowth of the long bones. These results suggest that a primary role of FGF signaling in the long bones is to act as a negative regulator of chondrocyte proliferation. These results are in contrast to our results that show that ectopic FGF9 expression in embryonic cranial mesenchymal cells induces overproliferation followed by endochondral ossification. How can these disparate observations be reconciled? One possible explanation is the differential timing of FGF9 expression. The Col2a1 promoter is active in the differentiated chondrocytes, while our transgenic FGF9 is expressed in undifferentiated cranial mesenchymal cells. Second, there are differences in the responding tissues. Chondrocytes in the long bones originate from the lateral plate mesoderm while the parietal mesenchyme is derived from cranial mesoderm. Since the stimulated cells have different developmental origins, there is no reason to expect that the responses will be identical. For example, although lens and corneal epithelial cells are related to each other, both morphologically and developmentally, they respond differently to FGF stimulation [29,44]. The reduction in proliferation in the long bones in response to FGF stimulation may be a unique property of the growth plate chondrocytes [4]. In contrast, the FGF9-induced proliferation of cranial mesenchymal cells is consistent with the notion that FGFs, in general, act as mitogens during normal development.
###end p 46
###begin title 47
Endogenous role for FGF9?
###end title 47
###begin p 48
###xml 228 233 228 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf9 </italic>
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 864 866 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 725 740 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1018 1033 <span type="species:ncbi:10090">transgenic mice</span>
Though FGF9 appears to be sufficient to induce chondrogenesis in the skull, the role of FGF9 during normal development of cartilage in the cranium is unclear. Our in situ hybridizations did not show any detectable expression of Fgf9 in the calvarial mesenchyme at E11 or E13. Expression is seen later during embryonic development in the endocranial portions of the mesenchyme and is downregulated during postnatal development [16]. This expression pattern suggests that FGF9 is not important for initial specification of the cells in the chondrocytic lineage in the cranium. Consistent with this model, targeted deletion of FGF9 does not result in any visible skeletal abnormalities in the skull [24,25]. In contrast, in the transgenic mice, the ectopic FGF9 plays an instructive role and initiates chondrogenesis. FGF9 is known to signal through FGFR2 and FGFR3 [45]. Signaling by FGF9 in the transgenic heads is likely to be mediated initially through FGFR2 rather than FGFR3 as the parietal fate switch in the FGF9 transgenic mice is not rescued by the loss of FGFR3. After Sox9 expression has been induced and the chondrocytic program has been initiated (by E13), expression of the FGF9 transgene is no longer required. In contrast to the normal chondrocytic differentiation program in long bones, ectopic chondrogenesis in the cranium proceeds at a much slower rate. Though the reasons for this are presently unclear, we speculate that this may be due to the multi-step nature of the endochondral differentiation program. Respecification and reprogramming of the parietal environment is required, and this is accomplished in a less timely fashion than at the normal sites of differentiation.
###end p 48
###begin title 49
FGFRs and intramembranous ossification
###end title 49
###begin p 50
###xml 340 341 340 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 250 256 <span type="species:ncbi:9606">humans</span>
###xml 373 388 <span type="species:ncbi:10090">transgenic mice</span>
###xml 847 852 <span type="species:ncbi:9606">human</span>
###xml 853 861 <span type="species:ncbi:9606">patients</span>
###xml 1022 1026 <span type="species:ncbi:10090">mice</span>
###xml 1227 1242 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1408 1413 <span type="species:ncbi:9606">human</span>
###xml 1414 1422 <span type="species:ncbi:9606">patients</span>
Our findings are in apparent conflict with some of the current models for the roles of FGF receptors in intramembranous ossification. Autosomal dominant mutations in FGFR2 or FGFR3 lead to premature differentiation and fusion of the skull sutures in humans and these effects are thought to be the consequence of enhanced receptor activity [9]. Based upon such a model, our transgenic mice would be predicted to exhibit an analogous phenotype, i.e. craniosynostosis. Inappropriate activation of the receptors in the cranial mesenchyme would be predicted to lead to premature differentiation. However, our studies indicate that ligand-mediated activation of FGFR2 induces proliferation of embryonic cranial mesenchymal cells and subsequent differentiation into cartilage. By extrapolation then, our results imply that mutations in the FGFR2 gene in human patients do not result in ligand-independent constitutive activation of the receptor. This prediction is supported by the finding that targeted inactivation of FGFR2 in mice causes developmental alterations in cell types that are not affected by the putative gain-of-function mutations. An alternative explanation is that transient stimulation of FGFR2 (as seen in our FGF9 transgenic mice) may lead to a qualitatively different cellular response compared to sustained ligand-independent stimulation of FGFR2 (as seen in the gain-of-function mutations in human patients). In either case, our results show that a single FGF can function as an instructive signal, inducing a specific cell type to switch from one differentiation program to an autonomous, alternative differentiation pathway.
###end p 50
###begin title 51
Conclusion
###end title 51
###begin p 52
###xml 123 138 <span type="species:ncbi:10090">transgenic mice</span>
###xml 480 495 <span type="species:ncbi:10090">transgenic mice</span>
Although the mechanistic details of FGF9 stimulation of the cranial mesenchymal cells remain to be elucidated, the OVE1070 transgenic mice provide the first demonstration in vivo that an FGF can switch the differentiation program of immature cranial mesoderm. These results also demonstrate that mesoderm-derived cranial mesenchymal cells are developmentally flexible and can undergo either intramembranous or endochondral ossification in response to extracellular signals. These transgenic mice provide a model system in which to elucidate the molecular connection between stimulation of an FGFR (FGFR2) and induction of expression of a cell-fate-determining transcription factor (Sox9).
###end p 52
###begin title 53
Methods
###end title 53
###begin title 54
###xml 19 34 <span type="species:ncbi:10090">transgenic mice</span>
Generation of FGF9 transgenic mice
###end title 54
###begin p 55
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 141 146 141 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf9 </italic>
###xml 286 288 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 364 366 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 61 76 <span type="species:ncbi:10090">transgenic mice</span>
###xml 135 140 <span type="species:ncbi:10090">mouse</span>
###xml 298 302 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 374 389 <span type="species:ncbi:10090">transgenic mice</span>
###xml 483 487 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
The construction of the FGF9 transgene and the generation of transgenic mice have been described previously [29]. The coding region of mouse Fgf9 (a gift from Dr. David M. Ornitz, Washington University School of Medicine, St. Louis) was inserted between the alphaA-crystallin promoter [46] and the SV40 small t intron/polyadenylation sequences of the CPV2 vector [47]. FGF9 transgenic mice were identified by isolating genomic DNA and screening by PCR, using primers specific to the SV40 portion of the transgene: 5'-GTGAAGGAACCTTACTTCTGTGGTG-3' (SV40A) and 5'-GTCCTTGGGGTCTTCTACCTTTCTC-3' (SV40B). The PCR cycle conditions were as follows: denaturation at 94degreesC for 30 seconds, annealing at 58degreesC for 30 seconds and extension at 72degreesC for 60 seconds, for 35 cycles. A final extension step of 72degreesC for 10 minutes was included.
###end p 55
###begin title 56
Skeletal preparations
###end title 56
###begin p 57
###xml 62 64 62 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
Skeletal preparations were performed as described previously [48]. Briefly, embryos were first skinned, and eviscerated, then fixed in 95% alcohol. After fixation, the samples were stained with Alcian blue, for 1-2 days. The samples were then destained in 95% ethanol for eight hours, and cleared in 2% potassium hydroxide from eight hours to overnight depending on the size of the specimen. After clearing, the samples were stained in Alizarin red/1% potassium hydroxide overnight. The samples were cleared in 1% potassium hydroxide and 20% glycerol/1% potassium hydroxide for 2-3 days. Subsequently, the samples were allowed to harden in 1:1 95% ethanol/glycerol for one day and then transferred to absolute glycerol for storage and photography.
###end p 57
###begin title 58
Histological analyses
###end title 58
###begin p 59
For routine histology, embryos were obtained from timed pregnancies using FVB/N females that were mated to heterozygous FGF9 transgenic males. Embryos were delivered by Caesarean section, fixed in 10% formalin, dehydrated, embedded in paraffin, sectioned (5 mum) and stained with hematoxylin and eosin.
###end p 59
###begin title 60
Section in situ hybridizations
###end title 60
###begin p 61
###xml 109 115 109 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2a1</italic>
###xml 117 124 117 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10a1</italic>
###xml 126 130 126 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ihh </italic>
###xml 134 139 134 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sox9 </italic>
###xml 264 270 264 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CbfaI </italic>
###xml 274 286 274 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">osteocalcin </italic>
###xml 381 393 381 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf9, Fgfr2 </italic>
###xml 397 403 397 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr3 </italic>
###xml 542 544 542 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 636 637 636 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 664 669 664 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sox9 </italic>
###xml 683 688 683 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sox9 </italic>
###xml 728 732 728 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hind</italic>
###xml 751 756 751 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sox9 </italic>
###xml 798 804 798 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2a1</italic>
###xml 848 851 848 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 914 922 914 922 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10aI </italic>
###xml 946 949 946 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hin</italic>
###xml 969 977 969 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10a1 </italic>
###xml 1029 1033 1029 1033 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ihh </italic>
###xml 1057 1060 1057 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 1078 1082 1078 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ihh </italic>
###xml 1134 1139 1134 1139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf9 </italic>
###xml 1163 1166 1163 1166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kpn</italic>
###xml 1183 1188 1183 1188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf9 </italic>
###xml 1241 1247 1241 1247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CbfaI </italic>
###xml 1272 1275 1272 1275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 1293 1299 1293 1299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CbfaI </italic>
###xml 1351 1363 1351 1363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">osteocalcin </italic>
###xml 1385 1388 1385 1388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 1470 1476 1470 1476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2 </italic>
###xml 1501 1504 1501 1504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 1522 1528 1522 1528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr2 </italic>
###xml 1580 1586 1580 1586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr3 </italic>
###xml 1610 1613 1610 1613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hin</italic>
###xml 1633 1639 1633 1639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgfr3 </italic>
###xml 1784 1786 1784 1786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 87 92 <span type="species:ncbi:10090">Mouse</span>
###xml 242 247 <span type="species:ncbi:10090">Mouse</span>
###xml 585 589 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 745 750 <span type="species:ncbi:10090">mouse</span>
###xml 963 968 <span type="species:ncbi:10090">mouse</span>
###xml 1072 1077 <span type="species:ncbi:10090">mouse</span>
###xml 1177 1182 <span type="species:ncbi:10090">mouse</span>
###xml 1287 1292 <span type="species:ncbi:10090">mouse</span>
###xml 1400 1405 <span type="species:ncbi:10090">mouse</span>
###xml 1516 1521 <span type="species:ncbi:10090">mouse</span>
###xml 1627 1632 <span type="species:ncbi:10090">mouse</span>
To analyze the expression of different markers, in situ hybridizations were performed. Mouse cDNA clones for Col2a1, Col10a1, Ihh and Sox9 were obtained from Dr. Benoit DeCrombrugghe (University of Texas, MD Anderson Cancer Center, Houston). Mouse cDNA clones for CbfaI and osteocalcin were obtained from Dr. Gerard Karsenty (Baylor College of Medicine, Houston). cDNAs clones for Fgf9, Fgfr2 and Fgfr3 were obtained from Dr. David Ornitz (Washington University School of Medicine, St. Louis). To analyze expression of the FGF9 transgene, a [35S]-UTP-labeled riboprobe specific to the SV40 sequences of the transgene was made (see Fig. 1). To assay for endogenous Sox9 expression, a Sox9 antisense probe was synthesized using a HindIII-digested mouse Sox9 cDNA and T7 RNA polymerase (Promega). For Col2a1, the antisense probe was synthesized using EcoRI-digested DNA and T3 RNA polymerase. The antisense probe for Col10aI was synthesized using a HindIII-digested mouse Col10a1 cDNA and T3 RNA polymerase. The antisense probe for Ihh was synthesized using a BamHI-digested mouse Ihh cDNA and T7 RNA polymerase. The antisense probe for Fgf9 was synthesized using a KpnI-digested mouse Fgf9 cDNA and SP6 RNA polymerase. The antisense probe for CbfaI was synthesized using an EcoRI-digested mouse CbfaI cDNA and T7 RNA polymerase. The antisense probe for osteocalcin was synthesized using BamHI-digested mouse osteocalcin cDNA and T3 RNA polymerase. The antisense probe for Fgfr2 was synthesized using an EcoRI-digested mouse Fgfr2 cDNA and T7 RNA polymerase. The antisense probe for Fgfr3 was synthesized using a HindIII-digested mouse Fgfr3 cDNA and T3 RNA polymerase. In situ hybridizations on tissue sections were done using hybridization and washing conditions described previously [49]. The hybridized slides were soaked in Kodak NTB-2 emulsion, dried and exposed for 3-5 days at 4degreesC. Following development and fixation, the slides were lightly counterstained with hematoxylin.
###end p 61
###begin title 62
Proliferation assay
###end title 62
###begin p 63
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 417 418 417 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 377 392 <span type="species:ncbi:10090">transgenic mice</span>
DNA replication was examined by BrdU incorporation as described previously [50]. Cell proliferation was analyzed by counting the number of BrdU positive nuclei from more than 100 cells in a defined area in the parietal region in three serial sections from four (E11) or six (E13) nontransgenic and FGF9 transgenic heads. The counts for BrdU-positive cells in nontransgenic and transgenic mice were compared using the t-test (p < 0.01).
###end p 63
###begin title 64
Whole mount in situ hybridizations
###end title 64
###begin p 65
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 190 194 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
For whole mount in situ hybridizations, tissue samples were washed thrice in PBS and fixed in 4% paraformaldehyde. Hybridizations were performed using digoxygenin-labeled sense or antisense SV40 riboprobes following standard procedures [51].
###end p 65
###begin title 66
Histochemical detection of beta-galactosidase activity
###end title 66
###begin p 67
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 527 528 521 522 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 624 625 618 619 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Embryos were obtained from timed pregnancies of R26R homozygote females mated to OVE1070/Wnt1cre double transgenic males [36]. X-Gal staining was performed as described previously [44]. Briefly, heads of E17 embryos were collected and fixed for 2 hours at 4degreesC in 0.1 M phosphate buffer (pH 7.3) containing 2% paraformaldehyde, 0.2% glutaraldehyde. Following fixation, the tissue samples were rinsed thrice at room temperature in 0.1 M phosphate buffer (pH 7.3) containing 0.01% sodium deoxycholate, 0.02% NP-40, 2 mM MgCl2, then stained in an X-gal substrate solution (0.01% sodium deoxycholate, 0.02% NP-40, 2 mM MgCl2, 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 1 mg/ml X-gal in 0.1 M phosphate buffer (pH 7.3)).
###end p 67
###begin title 68
Authors' contributions
###end title 68
###begin p 69
###xml 124 128 <span type="species:ncbi:10090">mice</span>
VG designed and performed all the experiments and drafted the manuscript. PAO originated the idea to generate the CPV2-FGF9 mice, helped in the design of the experiments and the interpretation of the data and edited the manuscript. Both authors read and approved the manuscript.
###end p 69
###begin title 70
Acknowledgements
###end title 70
###begin p 71
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf9 </italic>
###xml 113 119 113 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CbfaI </italic>
###xml 123 135 123 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Osteocalcin </italic>
###xml 191 197 191 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col2a1</italic>
###xml 199 206 199 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col10a1</italic>
###xml 208 212 208 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ihh </italic>
###xml 216 221 216 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sox9 </italic>
###xml 58 63 <span type="species:ncbi:10090">mouse</span>
###xml 819 826 <span type="species:ncbi:4097">Tobacco</span>
We would like to thank Dr. David Ornitz for providing the mouse Fgf9 cDNA, Dr. Gerard Karsenty for providing the CbfaI and Osteocalcin cDNA clones, Dr. Benoit DeCrombrugghe for providing the Col2a1, Col10a1, Ihh and Sox9 cDNA clones. We are grateful to Gabriele Schuster for performing the microinjections, Long Vien for assistance in animal husbandry, Barbara Harris for help in histological analyses, Dr. Frank Lovicu for making the CPV2-FGF9 construct, Drs. Fred A. Pereira, Bernd Fritzsch and David Nichols for helpful suggestions, and Travis Bailey for help in using Adobe Photoshop. We also thank Drs. Gerard Karsenty and Brendan Lee for critically reading the manuscript and for insightful comments and suggestions. This work was supported by NIH grants EY-10448 and EY-10803 (PAO) and revenue from the Nebraska Tobacco Settlement Biomedical Research Development Fund (VG).
###end p 71
###begin article-title 72
Regulatory mechanisms in the pathways of cartilage and bone formation
###end article-title 72
###begin article-title 73
VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation
###end article-title 73
###begin article-title 74
Bone development
###end article-title 74
###begin article-title 75
FGF signaling in skeletal development
###end article-title 75
###begin article-title 76
Fibroblast growth factors
###end article-title 76
###begin article-title 77
###xml 98 103 <span type="species:ncbi:10090">mouse</span>
Fgfr1 and Fgfr2 have distinct differentiation- and proliferation- related roles in the developing mouse skull vault
###end article-title 77
###begin article-title 78
Integration of FGF and TWIST in calvarial bone and suture development
###end article-title 78
###begin article-title 79
###xml 80 85 <span type="species:ncbi:9606">human</span>
FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease
###end article-title 79
###begin article-title 80
FGF receptor mutations: dimerization syndromes, cell growth suppression, and animal models
###end article-title 80
###begin article-title 81
###xml 85 90 <span type="species:ncbi:10090">mouse</span>
Abnormalities in cartilage and bone development in the Apert syndrome FGFR2(+/S252W) mouse
###end article-title 81
###begin article-title 82
Uncoupling fibroblast growth factor receptor 2 ligand binding specificity leads to Apert syndrome-like phenotypes
###end article-title 82
###begin article-title 83
Differential regulation of endochondral bone growth and joint development by FGFR1 and FGFR3 tyrosine kinase domains
###end article-title 83
###begin article-title 84
The IIIc alternative of Fgfr2 is a positive regulator of bone formation
###end article-title 84
###begin article-title 85
Fibroblast growth factor receptor 3 is a negative regulator of bone growth
###end article-title 85
###begin article-title 86
Regulation of chondrocyte growth and differentiation by fibroblast growth factor receptor 3
###end article-title 86
###begin article-title 87
FGF-, BMP- and Shh-mediated signalling pathways in the regulation of cranial suture morphogenesis and calvarial bone development
###end article-title 87
###begin article-title 88
FGF2 promotes skeletogenic differentiation of cranial neural crest cells
###end article-title 88
###begin article-title 89
###xml 53 58 <span type="species:ncbi:10090">mouse</span>
Genomic organization and embryonic expression of the mouse fibroblast growth factor 9 gene
###end article-title 89
###begin article-title 90
###xml 79 84 <span type="species:ncbi:10090">mouse</span>
Expression of the Fgf6 gene is restricted to developing skeletal muscle in the mouse embryo
###end article-title 90
###begin article-title 91
###xml 96 101 <span type="species:ncbi:10090">mouse</span>
Pattern of keratinocyte growth factor and keratinocyte growth factor receptor expression during mouse fetal development suggests a role in mediating morphogenetic mesenchymal-epithelial interactions
###end article-title 91
###begin article-title 92
###xml 57 62 <span type="species:ncbi:10090">mouse</span>
Expression of the fibroblast growth factor-5 gene in the mouse embryo
###end article-title 92
###begin article-title 93
###xml 53 58 <span type="species:ncbi:10090">mouse</span>
FGF-7 (keratinocyte growth factor) expression during mouse development suggests roles in myogenesis, forebrain regionalisation and epithelial-mesenchymal interactions
###end article-title 93
###begin article-title 94
###xml 95 100 <span type="species:ncbi:9031">chick</span>
FGF-2 mRNA and its antisense message are expressed in a developmentally specific manner in the chick limb bud and mesonephros
###end article-title 94
###begin article-title 95
###xml 31 35 <span type="species:ncbi:10090">mice</span>
Male-to-female sex reversal in mice lacking fibroblast growth factor 9
###end article-title 95
###begin article-title 96
###xml 48 52 <span type="species:ncbi:10090">mice</span>
Lung hypoplasia and neonatal death in Fgf9-null mice identify this gene as an essential regulator of lung mesenchyme
###end article-title 96
###begin article-title 97
###xml 37 41 <span type="species:ncbi:10090">mice</span>
Apparent normal phenotype of Fgf6-/- mice
###end article-title 97
###begin article-title 98
Keratinocyte growth factor is required for hair development but not for wound healing
###end article-title 98
###begin article-title 99
FGF5 as a regulator of the hair growth cycle: evidence from targeted and spontaneous mutations
###end article-title 99
###begin article-title 100
###xml 92 107 <span type="species:ncbi:10090">transgenic mice</span>
Overlapping effects of different members of the FGF family on lens fiber differentiation in transgenic mice
###end article-title 100
###begin article-title 101
Patterning the optic neuroepithelium by FGF signaling and Ras activation
###end article-title 101
###begin article-title 102
Sox9 is required for cartilage formation
###end article-title 102
###begin article-title 103
SOX9 is a potent activator of the chondrocyte-specific enhancer of the pro alpha1(II) collagen gene
###end article-title 103
###begin article-title 104
Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation
###end article-title 104
###begin article-title 105
The osteoblast: a sophisticated fibroblast under central surveillance
###end article-title 105
###begin article-title 106
###xml 67 72 <span type="species:ncbi:9031">chick</span>
The triple origin of skull in higher vertebrates: a study in quail-chick chimeras
###end article-title 106
###begin article-title 107
Tissue origins and interactions in the mammalian skull vault
###end article-title 107
###begin article-title 108
Interactions and fates of avian craniofacial mesenchyme
###end article-title 108
###begin article-title 109
###xml 33 38 <span type="species:ncbi:10090">mouse</span>
Modification of gene activity in mouse embryos in utero by a tamoxifen-inducible form of Cre recombinase
###end article-title 109
###begin article-title 110
Generalized lacZ expression with the ROSA26 Cre reporter strain
###end article-title 110
###begin article-title 111
Fate of the mammalian cranial neural crest during tooth and mandibular morphogenesis
###end article-title 111
###begin article-title 112
Fate of the mammalian cardiac neural crest
###end article-title 112
###begin article-title 113
Up-regulation of the chondrogenic Sox9 gene by fibroblast growth factors is mediated by the mitogen-activated protein kinase pathway
###end article-title 113
###begin article-title 114
###xml 121 136 <span type="species:ncbi:10090">transgenic mice</span>
Skeletal dysplasia and defective chondrocyte differentiation by targeted overexpression of fibroblast growth factor 9 in transgenic mice
###end article-title 114
###begin article-title 115
Endogenous and ectopic gland induction by FGF-10
###end article-title 115
###begin article-title 116
Identification of fibroblast growth factor 9 (FGF9) as a high affinity, heparin dependent ligand for FGF receptors 3 and 2 but not for FGF receptors 1 and 4
###end article-title 116
###begin article-title 117
###xml 124 130 <span type="species:ncbi:10090">murine</span>
###xml 163 178 <span type="species:ncbi:10090">transgenic mice</span>
Lens-specific expression and developmental regulation of the bacterial chloramphenicol acetyltransferase gene driven by the murine alpha A- crystallin promoter in transgenic mice
###end article-title 117
###begin article-title 118
###xml 84 89 <span type="species:ncbi:10090">mouse</span>
TGF alpha can act as a chemoattractant to perioptic mesenchymal cells in developing mouse eyes
###end article-title 118
###begin article-title 119
###xml 80 95 <span type="species:ncbi:10090">transgenic mice</span>
Expression of a truncated FGF receptor results in defective lens development in transgenic mice
###end article-title 119
###begin article-title 120
Secreted FGFR3, but not FGFR1, inhibits lens fiber differentiation
###end article-title 120
###begin article-title 121
In situ hybridization : a practical approach
###end article-title 121

